Sunovion Pharmaceuticals
Sunovion Pharmaceuticals is a U.S.-based specialty pharmaceutical subsidiary of Sumitomo Pharma that discovers, develops, and commercializes branded therapeutics for CNS, respiratory, oncology, women's health, urology, rare disease, and cell & gene therapy patients.
- Company typePrivate
- Founded1984
- HeadquartersMarlborough, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sunovion Pharmaceuticals does
Sunovion Pharmaceuticals Inc., founded in 1984 and headquartered in Marlborough, Massachusetts, is a U.S.-based specialty pharmaceutical company that discovers, develops, and commercializes therapeutic products primarily for patients with central nervous system (CNS) and respiratory disorders. Through its parent company Sumitomo Pharma America (SMPA), a U.S. subsidiary of Japanese pharmaceutical group Sumitomo Pharma Co., Ltd., the company maintains a diversified pipeline spanning oncology, women's health, urology, rare disease, CNS, and cell & gene therapies. Sunovion's product portfolio includes FDA-approved branded specialty pharmaceuticals (notably in CNS and respiratory), and the company has historically expanded through acquisitions — most notably Elevation Pharmaceuticals in 2012 ($430M, respiratory) and Cynapsus Therapeutics in 2016 ($624M, Parkinson's/CNS). The firm employs 5,001–10,000 people and operates as a privately held subsidiary, with no separately disclosed financials.
Sunovion generates revenue through standard pharmaceutical commercialization: branded prescription drugs sold via hospital pharmacies, retail pharmacies, and online pharmacies globally. Its go-to-market leverages the regulatory approvals and clinical evidence base of its branded products, distributed through traditional pharma channels rather than direct-to-consumer or technology-platform models. Pricing is not publicly disclosed, consistent with B2B/B2B2C pharmaceutical pricing where reimbursement is negotiated through insurers, pharmacy benefit managers (PBMs), and government payers. Recent strategic activity includes a 2023 partnership with Bod Science Pty Ltd to advance an investigational insomnia therapy, signaling continued investment in CNS-adjacent therapeutic areas. No AI/ML capabilities, proprietary technology platforms, or software products are disclosed in the available source material — the company's competitive positioning rests on regulatory approvals, clinical data, capital backing from its Japanese parent, and a diversified therapeutic pipeline.
Sunovion Pharmaceuticals firmographics
Firmographics- Name
- Sunovion Pharmaceuticals
- Website
- https://sunovion.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sunovion Pharmaceuticals is a U.S.-based specialty pharmaceutical subsidiary of Sumitomo Pharma that discovers, develops, and commercializes branded therapeutics for CNS, respiratory, oncology, women's health, urology, rare disease, and cell & gene therapy patients.
- Ownership category
- akta.pro rank
Sunovion Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Sunovion Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Marlborough
- HQ country
- United States
- HQ region
- North America
Markets served
Sunovion Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Distribution channels3 records
Marketing channels3 records
Sunovion Pharmaceuticals product offering
Product offeringCore offering
Sunovion Pharmaceuticals discovers, develops, and commercializes therapeutic products focused on central nervous system (CNS) disorders and respiratory diseases. Through its parent Sumitomo Pharma America, the business extends across oncology, women's health, urology, rare disease, and cell and gene therapies, with active preclinical and clinical programs addressing unmet medical needs.
Product overview
Sumitomo Pharma America (SMPA), parent company of Sunovion Pharmaceuticals, operates a diversified pharmaceutical business focused on drug discovery, development, and commercialization across multiple therapeutic areas including oncology, women's health, urology, rare disease, CNS (central nervous system), and cell & gene therapies. The company maintains a pipeline of preclinical and clinical programs targeting areas of unique and unmet medical need. No specific Sunovion-branded products or named offerings are detailed in the available source material.
Differentiator
Problem solved
Functional benefit
Products and services
- CNS therapeutics portfolio
Companies that use Sunovion Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Sunovion Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sunovion Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bod Science Pty LtdminorDutch company dsm-firmenich N.V. partnered with Australia's Bod Science Pty Ltd to advance an investigational insomnia therapy using GMP-grade pharmaceutical products to support clinical trials and regulatory approval.
Scale indicators6 records
Recent moves4 records
Expansion highlights4 records
Sunovion Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Lundbeck: Lundbeck is a global specialty pharmaceutical company dedicated to CNS disorders, including depression, schizophrenia, Parkinson's disease, and rare neurological conditions. It is a direct competitor to Sunovion's CNS franchise and operates at comparable scale.
- Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company with a strong CNS franchise (sleep, epilepsy, psychiatry) and recent oncology expansion. It is directly comparable to Sunovion in therapeutic area focus, mid-sized specialty positioning, and US commercialization model.
- Acadia Pharmaceuticals: Acadia Pharmaceuticals is a specialty CNS company focused on neurological disorders, including Parkinson's disease psychosis (Nuplazid) and Rett syndrome. It directly competes with Sunovion in CNS specialty therapeutics at a similar scale.
- Theravance Biopharma: Theravance is a mid-sized specialty pharmaceutical company with a focus on respiratory therapeutics (including Yupelri for COPD). It is directly comparable to Sunovion's respiratory franchise and shares the mid-cap specialty pharma model.
- Intra-Cellular Therapies: Intra-Cellular Therapies develops and commercializes CNS therapeutics, most notably Caplyta for schizophrenia and bipolar depression. It is a comparable specialty CNS pharmaceutical company with similar scale and commercial focus to Sunovion.
- Supernus Pharmaceuticals: Supernus is a US specialty pharma focused on CNS disorders, particularly epilepsy, ADHD, and Parkinson's disease. It directly competes with Sunovion's CNS franchise and shares a similar mid-cap specialty pharma business model.
Broad incumbents
- Takeda Pharmaceutical Company: Takeda is a large Japanese-headquartered pharmaceutical company with substantial US operations in CNS, gastroenterology, and rare diseases. Comparable to Sunovion/Sumitomo as another Japanese pharma parent with US specialty pharmaceutical footprint.
- Otsuka Pharmaceutical Development & Commercialization: Otsuka is a major Japanese pharmaceutical company's US operation with significant CNS presence (Abilify, Abilify Asimtufii). Comparable to Sunovion as a Japanese pharma US subsidiary with a strong CNS specialty focus and similar cross-border parent-subsidiary structure.
- Eisai Inc. Eisai is a Japanese pharmaceutical company's US subsidiary with established CNS (Alzheimer's, insomnia) and oncology franchises. It shares Sunovion's positioning as a Japan-headquartered pharma's US CNS-focused subsidiary with diversified therapeutic area ambitions.
- Astellas Pharma US: Astellas is a Japanese pharmaceutical company's US subsidiary with focus areas including oncology, women's health, and rare disease. It is comparable to Sunovion as a Japan-headquartered pharma's US specialty operation with a diversified therapeutic portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sunovion Pharmaceuticals social profiles
Digital presenceSunovion Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sunovion Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles9 records
Sunovion Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sunovion Pharmaceuticals M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sunovion Pharmaceuticals
What does Sunovion Pharmaceuticals do?
Sunovion Pharmaceuticals discovers, develops, and commercializes therapeutic products focused on central nervous system (CNS) disorders and respiratory diseases. Through its parent Sumitomo Pharma America, the business extends across oncology, women's health, urology, rare disease, and cell and gene therapies, with active preclinical and clinical programs addressing unmet medical needs.
Is Sunovion Pharmaceuticals a public or private company?
Sunovion Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Sunovion Pharmaceuticals founded?
Sunovion Pharmaceuticals was founded in 1984. It employs 5,001 to 10,000 people.
Where is Sunovion Pharmaceuticals based?
Sunovion Pharmaceuticals is headquartered in Marlborough, United States, in the North America region.
Who are Sunovion Pharmaceuticals's main competitors?
Direct peers on record are Lundbeck, Jazz Pharmaceuticals, Acadia Pharmaceuticals, Theravance Biopharma, Intra-Cellular Therapies and Supernus Pharmaceuticals. Broad incumbents are Takeda Pharmaceutical Company, Otsuka Pharmaceutical Development & Commercialization, Eisai Inc. and Astellas Pharma US.
Does Sunovion Pharmaceuticals have an API?
No public API is recorded for Sunovion Pharmaceuticals.
What industry is Sunovion Pharmaceuticals in?
Sunovion Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2833.